Merck Sharpe and Dohme launches new Ivemend treatment in UK

Merck Sharpe and Dohme has announced the UK launch of a new formulation of its drug Ivemend, which combats nausea and vomiting associated with chemotherapy.

The 150 mg single-dose intravenous formulation of the fosaprepitant dimeglumine treatment represents a simpler method of addressing the condition, which is among the most feared side-effects of highly emetogenic cisplatin-based cancer chemotherapy.

Previously, patients were required to receive intravenous or capsule-based drug administrations over three days, whereas the new Ivemend therapy is used on the first day of chemotherapy only.

Elaine Lennan, consultant cancer nurse at the Southampton University Hospitals Trust, said the launch is a "welcome addition" to the range of products available for tackling chemotherapy-induced nausea and vomiting (CINV).

"Availability of this new option will offer health professionals flexibility in personalising anti-sickness regimens and help them focus on preventing rather than treating CINV," she stated.

Earlier this month, Merck Sharpe and Dohme announced its 2010 financial results, noting significant growth following its 2009 merger with Schering-Plough.